Tempus AI Lifts Lung Cancer Testing by 24% at ASCO — May 29, 2026

ASCO twenty twenty-six opens today, and AI just lifted lung-cancer biomarker testing by twenty-four percent.Run time: 19:27In today's episode:Tempus Next lifts lung-cancer biomarker testing by twenty-four percentMayo Clinic brings thirty oncology AI studies to ASCOSylvester AI reads bone marrow to personalize myeloma therapyPenn Medicine flags AI gaps in patient cancer infoNEJM AI publishes MEDS open data standard for health AIAnthropic ships Claude Opus four point eight with dynamic workflowsAnthropic in talks to raise sixty-five billion at nine-hundred-sixty-five billionMythos moves toward broader release after ten thousand bugs foundTL;DR:ASCO 2026 kicks off in Chicago today — Tempus Next's AI clinical decision support lifted real-world biomarker-testing rates by +24% ALK, +18% EGFR, +13% PD-L1 in early-stage NSCLC across six community health systems, a rare deployed-AI outcomes win.Anthropic released Claude Opus 4.8 yesterday — high-effort default, dynamic workflows spawning hundreds of parallel subagents, agentic coding jumps 64.3→69.2%, ~4× fewer flawed-code passes, fast mode 3× cheaper. Pricing held at $5/$25 per M tokens.NEJM AI published the MEDS (Medical Event Data Standard) review on May 28 — an open data framework now used at 21 institutions and 27 papers that aims to fix reproducibility/portability in EHR-based clinical AI.Sources cited:businesswireMayo News NetworkNewswisePenn MedicineNEJM AIHarvard Science ReviewAnthropicTechCrunchUS NewsMEDS overviewSubscribe: YouTubemedAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.